Publicis Health global CEO Matt McNally taps in for 2026

Episode Description

Few people in medical marketing have as accomplished of a track record as Matt McNally.

Over the course of more than three decades, Matt has worked across numerous major holding companies and impacted the industry in innumerable ways.

In late 2024, he found his career at an inflection point.

Having led Omnicom Health Group for a few years, his future was put in question when Omnicom announced its multibillion dollar takeover of holding company rival IPG.

As industry stakeholders speculated about whether he or IPG Health CEO Dana Maiman would lead the new Omnicom Health vertical post-merger, Matt submitted his resignation, effective January 1, 2025.

Then, just over a week later, he returned to Publicis to serve as global CEO of Publicis Health.

In his first year on the job, Publicis Health has benefited from the robust performance of MM+M Agency 100 honorees like Digitas Health, Heartbeat, Razorfish Health and Saatchi & Saatchi Wellness.

Additionally, Publicis Health welcomed medcomms agency P-value Group into the fold over the summer.

On this week’s episode, McNally joins us to talk about how his return to Publicis Health has gone, what he makes of the new-look Omnicom and what else is on his radar for 2026. It’s a conversation with a medical marketing tastemaker that you won’t want to miss.

For our Trends segment, we have a few updates on those Untitled Letters the FDA has been sending out to drugmakers.